Epic Sciences

In the News

03.14.2019

CTC AR-V7 Validated as Predictive Marker of Resistance to AR-Directed Therapy in mCRPC

Nuclear-localized androgen receptor splice variant 7 (AR-V7) protein in circulating tumor cells (CTCs) is a predictive marker of shorter progression-free and overall survival (OS) with antiandrogen therapy in patients with metastatic castration-resistant prostate cancer (mCRPC), according to results from the phase III PROPHECY trial that were published in the Journal of Clinical Oncology.

03.14.2019

Blood Test Study Meets Goal, Validates Epic’s Prostate Cancer Target

Epic Sciences has commercialized a blood test that can predict how likely a patient with late-stage prostate cancer treated with hormones is likely to respond to an additional course of such therapy. Now, the San Diego-based company has additional data that it says supports use of its tests to determine when not to use hormone therapy.

03.13.2019

Blood Tests Predict Effectiveness of Hormonal Therapies

A multi-institutional group of clinical researchers, led by the Duke Cancer Institute’s Andrew Armstrong, MD, McS, FACP, published a new report this month in the Journal of Clinical Oncology, that describes results from the PROPHECY study, which prospectively compared two blood tests to assess how well they predicted the effectiveness of hormonal therapy in men with metastatic prostate cancer.

02.17.2019

ASCO GU 2019: A Phase II Trial in Progress: Pamiparib, an Investigational PARP Inhibitor, in Patients with mCRPC and a Circulating Tumor Cell Homologous Recombination Deficiency Phenotype or BRCA Defects

San Francisco, CA (UroToday.com) Prostate cancer is one of the leading causes of cancer deaths in men. Patients with metastatic castration-resistant prostate cancer (mCRPC) who have a BRCA1/2 mutation or mutations in other homologous recombination deficiency genes have aggressive disease and a worse prognosis. Poly (ADP-ribose) polymerase (PARP) proteins are a family of proteins involved in DNA repair, genome stability, and programmed cell death. Inhibition of PARP proteins allows for the accumulation of unrepaired single-strand breaks, which are converted to double-strand breaks during cell division and can lead to apoptosis/cell death. DNA repair can be compromised by the absence of homologous recombination components such as BRCA1 or BRCA2.

01.08.2019

Circulating Tumor Cell Capture Technologies Expand in 2018

NEW YORK (GenomeWeb) – The market for circulating tumor cell (CTC) capture and detection grew significantly in 2018 as several companies pushed toward clinical implementation of their technologies for diagnosing multiple cancers, while new firms spun out of academic institutions with their own technologies. In order to diagnose cancer clinicians have traditionally performed tissue biopsies, which can be invasive, expensive, and time-consuming for patients. Over the last decade, however, liquid biopsy tools have emerged as a way to address these issues and perhaps provide a more accurate picture of individual patients' disease.

01.08.2019

The Race to Diagnose Cancer With a Simple Blood Test

Five years ago, a team of researchers pored over the results of a prenatal genetic test given to more than 125,000 healthy pregnant women and made a stunning discovery. The blood test, marketed by gene-sequencing giant Illumina, was designed to detect chromosome anomalies associated with conditions such as Down syndrome by analyzing fragments of fetal DNA circulating in the mother’s blood. In 3,757 of the tests, the scientists found at least one abnormality. But in 10 of those cases, further analysis revealed that the fetuses were in fact normal. “In every one of those 10 cases, it turned out there was an undiagnosed cancer” in the mother, says Alex Aravanis, who at the time of the study was the senior director of research and development at Illumina.

12.12.2018

New Study Reports Blood Test Can Predict Optimal Treatment for Advanced Prostate Cancer

San Diego, Coherent Chronicle — Researchers from Lawson Health Research Institute suggested that a blood test can help predict efficiency of a treatment in advanced prostate cancer. The Lawson Health Research Institute in collaboration with the Memorial Sloan Kettering Cancer Center and the Royal Marsden and Epic Sciences, demonstrated that a blood test can predict the responses of patients suffering from advanced prostate cancer to specific treatments.